Idiopathic Perifoveal Telangiectasis is commonly referred to as macular telangiectasia, a retinal disorder that affects the center most part of the macula. This poorly understood disease is most common in people between 40 to 60 years old. Dilated and leaky retinal capillaries develop around the temporal part of the foveal area and may eventually encompass the entire area, causing pigmentation to migrate below the retina and into the vitreoretinal interface. As this progresses, visual clarity decreases.
Unfortunately, there are no known treatments that have been successful in treating idiopathic perifoveal telangiectasia, but in certain cases, injection of anti-VEGF agents, such as Bevacizumab (Avastin), Lucentis, or Eylea may be beneficial.